e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease
Today a large number of studies are focused on clarifying the complexity and diversity of the pathogenetic mechanisms inducing Parkinson disease. We used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin that induces Parkinson disease, to evaluate the change of midbrain structure and...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2016/3937057 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562875219050496 |
|---|---|
| author | Samuela Cataldi Michela Codini Stéphane Hunot François-Pierre Légeron Ivana Ferri Paola Siccu Angelo Sidoni Francesco Saverio Ambesi-Impiombato Tommaso Beccari Francesco Curcio Elisabetta Albi |
| author_facet | Samuela Cataldi Michela Codini Stéphane Hunot François-Pierre Légeron Ivana Ferri Paola Siccu Angelo Sidoni Francesco Saverio Ambesi-Impiombato Tommaso Beccari Francesco Curcio Elisabetta Albi |
| author_sort | Samuela Cataldi |
| collection | DOAJ |
| description | Today a large number of studies are focused on clarifying the complexity and diversity of the pathogenetic mechanisms inducing Parkinson disease. We used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin that induces Parkinson disease, to evaluate the change of midbrain structure and the behavior of the anti-inflammatory factor e-cadherin, interleukin-6, tyrosine hydroxylase, phosphatase and tensin homolog, and caveolin-1. The results showed a strong expression of e-cadherin, variation of length and thickness of the heavy neurofilaments, increase of interleukin-6, and reduction of tyrosine hydroxylase known to be expression of dopamine cell loss, reduction of phosphatase and tensin homolog described to impair responses to dopamine, and reduction of caveolin-1 known to be expression of epithelial-mesenchymal transition and fibrosis. The possibility that the overexpression of the e-cadherin might be implicated in the anti-inflammatory reaction to MPTP treatment by influencing the behavior of the other analyzed molecules is discussed. |
| format | Article |
| id | doaj-art-67b29e679f68432384a3602c860f3ce7 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-67b29e679f68432384a3602c860f3ce72025-02-03T01:21:36ZengWileyMediators of Inflammation0962-93511466-18612016-01-01201610.1155/2016/39370573937057e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson DiseaseSamuela Cataldi0Michela Codini1Stéphane Hunot2François-Pierre Légeron3Ivana Ferri4Paola Siccu5Angelo Sidoni6Francesco Saverio Ambesi-Impiombato7Tommaso Beccari8Francesco Curcio9Elisabetta Albi10Department of Pharmaceutical Science, University of Perugia, 06100 Perugia, ItalyDepartment of Pharmaceutical Science, University of Perugia, 06100 Perugia, ItalyInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Université Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle ÉPINIÈRE, ICM, 75013 Paris, FranceInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Université Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle ÉPINIÈRE, ICM, 75013 Paris, FranceInstitute of Pathologic Anatomy and Histology, University of Perugia, 06100 Perugia, ItalyInstitute of Pathologic Anatomy and Histology, University of Perugia, 06100 Perugia, ItalyInstitute of Pathologic Anatomy and Histology, University of Perugia, 06100 Perugia, ItalyDepartment of Clinical and Biological Sciences, University of Udine, 33100 Udine, ItalyDepartment of Pharmaceutical Science, University of Perugia, 06100 Perugia, ItalyDepartment of Clinical and Biological Sciences, University of Udine, 33100 Udine, ItalyDepartment of Pharmaceutical Science, University of Perugia, 06100 Perugia, ItalyToday a large number of studies are focused on clarifying the complexity and diversity of the pathogenetic mechanisms inducing Parkinson disease. We used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin that induces Parkinson disease, to evaluate the change of midbrain structure and the behavior of the anti-inflammatory factor e-cadherin, interleukin-6, tyrosine hydroxylase, phosphatase and tensin homolog, and caveolin-1. The results showed a strong expression of e-cadherin, variation of length and thickness of the heavy neurofilaments, increase of interleukin-6, and reduction of tyrosine hydroxylase known to be expression of dopamine cell loss, reduction of phosphatase and tensin homolog described to impair responses to dopamine, and reduction of caveolin-1 known to be expression of epithelial-mesenchymal transition and fibrosis. The possibility that the overexpression of the e-cadherin might be implicated in the anti-inflammatory reaction to MPTP treatment by influencing the behavior of the other analyzed molecules is discussed.http://dx.doi.org/10.1155/2016/3937057 |
| spellingShingle | Samuela Cataldi Michela Codini Stéphane Hunot François-Pierre Légeron Ivana Ferri Paola Siccu Angelo Sidoni Francesco Saverio Ambesi-Impiombato Tommaso Beccari Francesco Curcio Elisabetta Albi e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease Mediators of Inflammation |
| title | e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease |
| title_full | e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease |
| title_fullStr | e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease |
| title_full_unstemmed | e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease |
| title_short | e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease |
| title_sort | e cadherin in 1 methyl 4 phenyl 1 2 3 6 tetrahydropyridine induced parkinson disease |
| url | http://dx.doi.org/10.1155/2016/3937057 |
| work_keys_str_mv | AT samuelacataldi ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease AT michelacodini ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease AT stephanehunot ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease AT francoispierrelegeron ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease AT ivanaferri ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease AT paolasiccu ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease AT angelosidoni ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease AT francescosaverioambesiimpiombato ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease AT tommasobeccari ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease AT francescocurcio ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease AT elisabettaalbi ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease |